Table 2. Prognostic assessment of exosomal miR-21 expression with 3clinical features for recurrent glioma patients.
| Exosomal miR-21: No. of Patients | ||||
|---|---|---|---|---|
| Total No | High Expression Group | Low Expression Group | P | |
| Pattern Of Recurrence | ||||
| Local Tumor bed | 37 | 10 | 27 | |
| Diffuse intracranial or/and spinal dissemination | 33 | 25 | 8 | <0.001 |
| Interval To Recurrence (Median ± SD, m) | 26.4 ± 22.0 | 23.0 ± 20.7 | 0.432 | |
| Treatment | ||||
| Re-operation | 6 | 1 | 5 | |
| Chemotherapy | 64 | 34 | 30 | 0.09 |
| Overall follow-up time(months) | 2–90 | 1–102 | ||
| Survival | ||||
| Alive | 42 | 12 | 25 | 0.002 |
| Deceased | 28 | 23 | 10 | |
Abbreviations: SD, standard deviation; m, month; P < 0.05.